Robert Geho

Robert Geho is a co-founder and CEO of Diasome Pharmaceuticals, Inc. In his role at Diasome, he leads the management and strategic direction of the Company’s Phase 3-enabled targeted insulin therapies, as well as the development of Diasome’s novel Type 2 diabetes technology and oral therapy for obesity. In addition to his responsibilities at Diasome, he is a co-founder and director of SDG, Inc., a nanotechnology therapeutics company that is an Equity Partner Company of the Cleveland Clinic Foundation in Cleveland, Ohio. Mr. Geho has led or co-led multiple rounds of financing for several biotechnology companies, and he has been a key participant in the formation of multiple life sciences focused companies. He received both his undergraduate degree and MBA from Case Western Reserve University. Mr. Geho also serves as a member of the board of directors of the Diabetes Hands Foundation in Berkeley, CA.